Evidence for functional release of endogenous opioids in the locus ceruleus during stress termination.
Endogenous opioids target noradrenergic locus ceruleus (LC) neurons and potently inhibit LC activity. Nonetheless, it has been difficult to demonstrate functional regulation of the LC-noradrenergic system by endogenous opioids because of the lack of effect of opiate antagonists. The present findings provide evidence that endogenous opioids regulate LC neuronal activity during the termination of a stressor. LC neuronal discharge was recorded from halothane-anesthetized rats before, during, and after hypotensive stress elicited by intravenous nitroprusside infusion. In naive rats, mean arterial blood pressure was temporally correlated with LC activity such that hypotension was associated with increased LC discharge and a return to the normotensive state was associated with a decrease in LC discharge below pre-stress values. After microinfusion of an antagonist of the stress neuropeptide corticotropin-releasing factor (CRF) into the LC, the increase in LC discharge associated with hypotension was prevented, whereas LC inhibition associated with termination of the challenge occurred at an earlier time and was of a greater magnitude. In contrast, microinfusion of naloxone into the LC completely abolished LC inhibition associated with termination of the stressor. Naloxone microinfusion did not prevent LC inhibition associated with hypertension produced by intravenous vasopressin administration, suggesting that endogenous opioids may be selectively engaged during the termination of hypotensive stress. These results provide evidence for a functional release of endogenous opioids within the LC. This action of endogenous opioids may serve to counterbalance excitatory effects of CRF on the LC-norepinephrine system, thereby limiting its activation by stress.
Curtis
A L
AL
The Children's Hospital of Philadelphia, 706 Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104, USA.
Bello
N T
NT
Valentino
R J
RJ
D000818:Animals; D001794:Blood Pressure; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors; D007022:Hypotension / Q000139:chemically induced / Q000503:physiopathology*; D007275:Injections, Intravenous; D008125:Locus Coeruleus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008845:Microinjections; D009270:Naloxone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage; D009433:Neural Inhibition / Q000187:drug effects; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009599:Nitroprusside; D018847:Opioid Peptides / Q000378:metabolism* / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage; D051381:Rats; D017207:Rats, Sprague-Dawley; D013312:Stress, Physiological / Q000139:chemically induced / Q000503:physiopathology*; D014667:Vasopressins / Q000008:administration & dosage
C083591:H-R corticotropin-releasing factor (12-41), Phe(12)-Nle(21,38), C(alpha-MeLeu(37))-; D009292:Narcotic Antagonists; D018847:Opioid Peptides; D010446:Peptide Fragments; C113202:phenylalanyl corticotropin-releasing factor (12-41); D014667:Vasopressins; D009599:Nitroprusside; D009270:Naloxone; D003346:Corticotropin-Releasing Hormone